| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Complement C5a | HOT C5A-H5116 | Human Complement C5a Protein, Tag Free | Human | E. coli | ![]() | SDS-PAGE | $245.00 50ug | |
| Complement C5a | HOT C5A-H51H9 | Human Complement C5a Protein, His Tag | Human | E. coli | ![]() | SDS-PAGE | $245.00 50ug | |
| Complement C5a | HOT C5A-C5118 | Cynomolgus Complement C5a Protein, Tag Free | Cynomolgus | E. coli | ![]() | SDS-PAGE | $390.00 100ug | |
| Complement C5a | HOT C5A-C51H9 | Cynomolgus Complement C5a Protein, His Tag | Cynomolgus | E. coli | ![]() | SDS-PAGE | $245.00 50ug | |
| Complement C5a | HOT C5A-M51H4 | Mouse Complement C5a Protein, His Tag | Mouse | E. coli | ![]() | SDS-PAGE | $360.00 100ug | |
| Complement C5a | Human Complement C5a Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| BDB-001 | BDB-001; BDB001; BDB 001; BDB-1 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Vasculitis | Details |
| STSA-1002 | STSA-1002; STSA1002 | Phase 3 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Vilobelimab | IFX-1; CaCP-29 | Approved | Inflarx Nv | Gohibic | EU | Respiratory Distress Syndrome, Adult | Inflarx Nv, Inflarx Gmbh | 2025-01-13 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma, Squamous Cell; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Microscopic Polyangiitis; Pyoderma Gangrenosum; Respiratory Distress Syndrome, Adult; Sepsis; Shock, Septic; Systemic Inflammatory Response Syndrome | Details |
